New drug combo shows promise in shrinking esophageal tumors before surgery
NCT ID NCT07430579
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug adebrelimab to standard chemotherapy before surgery can help eliminate or shrink esophageal cancer more effectively. About 25 people with stage II/III esophageal squamous cell carcinoma will receive the combination, then have surgery. Researchers will check how many have no cancer left after treatment and monitor side effects and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE-RELATED ADVERSE EVENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Qilu Hospital of Shandong University
RECRUITINGJinan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tape to tame Post-Surgery face swelling?
- Can a virtual meadow or a Mind's eye stream calm hospital anxiety?
- Smartwatch could spot nerve damage before it starts
- Can healing at home beat hospital care for bedsores?
- Can virtual reality make knee pain therapy more engaging?
- Can sound waves outperform needles for Jumper's knee?